Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
News|Articles|October 15, 2025
The Menopause Society prepares to convene in Orlando for 2025 Annual Meeting
Author(s)Morgan Ebert
Fact checked by: Celeste Krewson, Assistant Editor
The Menopause Society’s 2025 meeting heads to Orlando with sessions on longevity, hormones, cognition, and care innovation at midlife and beyond.
Advertisement
Advertisement
The Menopause Society will host its 2025 Annual Meeting from October 21–25 at the Hyatt Regency Orlando, welcoming clinicians, researchers, and women’s health experts from around the world. This year’s theme, “Optimizing Health and Longevity at Menopause and Beyond,” reflects a program designed to address the evolving needs of midlife and older women.
Related to this article
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
Advertisement
Advertisement